Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Remix Therapeutics | 2024 | Venture - Series Unknown | Undisclosed | Cambridge |
| ENB Therapeutics | 2022 | Series A | Undisclosed | New York |
| Meiogenix | 2024 | Series A | Undisclosed | Paris |
| TwoStep Therapeutics | 2026 | Series A | $21.1M | Palo Alto |
| Variant Bio | 2021 | Series B | Undisclosed | Seattle |
| Accipiter Biosciences | 2025 | Seed | Undisclosed | Seattle |
| Cajal Neuroscience | 2022 | Series A | Undisclosed | Seattle |
| CIBO | 2024 | Series C | Undisclosed | Saint Louis Park |
| Recludix Pharma | 2026 | Undisclosed | Undisclosed | San Diego |
| Eclipse Bioinnovations | 2025 | Venture - Series Unknown | $4.9M | San Diego |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 51 | Remix Therapeutics | Venture - Series Unknown | Undisclosed | Cambridge, United States |
| 52 | ENB Therapeutics | Series A | Undisclosed | New York, United States |
| 53 | Meiogenix | Series A | Undisclosed | Paris, France |
| 54 | TwoStep Therapeutics | Series A | $21.1M | Palo Alto, United States |
| 55 | Variant Bio | Series B | Undisclosed | Seattle, United States |
| 56 | Accipiter Biosciences | Seed | Undisclosed | Seattle, United States |
| 57 | Cajal Neuroscience | Series A | Undisclosed | Seattle, United States |
| 58 | CIBO | Series C | Undisclosed | Saint Louis Park, United States |
| 59 | Recludix Pharma | Undisclosed | Undisclosed | San Diego, United States |
| 60 | Eclipse Bioinnovations | Venture - Series Unknown | $4.9M | San Diego, United States |
Remix Therapeutics is a biotechnology company that is working on developing small molecule medicines.
ENB Therapeutics develops therapies to break barriers that prevent the majority of patients from responding to immunotherapy agents.
Meiogenix is a biotechnology company that develops breeding technologies.
TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics.
Accipiter Biosciences is a biotechnology company.
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
CIBO scales regenerative advanced platform technology that connects growers to incentives and enterprises to growers.
Recludix pharma is a developing platform to treat cancer patients.
Eclipse Bioinnovations is an RNA genomics company that provides products and services to academic and industry customers around the world.
Halio is developing adaptive, dynamic glass for the commercial, residential, and automotive markets.
Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases.
Immunai is a biotech company that provides mapping and reprogramming immunology, machine learning, and software engineering.
Matchpoint Therapeutics is a biotechnology company that integrates chemoproteomics, ML, and covalent chemistry to treat serious illnesses.
Invaio Sciences is a technology company that is dedicated to solving pressing agriculture, nutrition, and environmental challenges.
CrossBridge Bio operates as a biotechnology company.
Tr1x is a biotechnology company developing novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.
NILO Therapeutics is a biotechnology and therapeutics company.
AeroRx Therapeutics is a biopharmaceutical company that developing proprietary, combination products.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.
Thryv Therapeutics is a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias.
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.
Leal Therapeutics develops novel therapeutics for patients.
Harpe Bio develops sustainable weed control solutions for organic and industrial agriculture.
Alexandria Venture Investments has invested in 157 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Alexandria Venture Investments's top investment sectors include Biotechnology, Therapeutics, Medical, Health Care, Life Science. The firm invests across 32 different industry categories.
Among tracked funding rounds, Crystalys Therapeutics received $205.0M in a Series A round. Alexandria Venture Investments's total known invested capital is $3.8B.
Alexandria Venture Investments's average investment size is $37.7M across its portfolio of 157 companies.
Recent Alexandria Venture Investments portfolio additions include Remix Therapeutics, ENB Therapeutics, Meiogenix, TwoStep Therapeutics, Variant Bio. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors